{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:52Z","timestamp":1787009452839,"version":"build-2736575974"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare clinical outcomes of patients treated with liposomal amphotericin B (L-AmB) versus mold-active triazoles as primary treatment for invasive aspergillosis (IA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study of adult patients treated with either L-AmB or triazoles for proven or probable IA at 2 academic hospitals over a 10-year period. The primary endpoint was all-cause 90-day mortality from IA diagnosis. Landmark trial emulation at day 7 postdiagnosis was used to compare initial triazole versus L-AmB for IA. Confounding by indication was addressed using inverse probability of treatment weighting (IPTW) with stabilized weights, and treatment effects were estimated using Cox regression with both IPTW and covariate adjustment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 401 patients were included. Median age 65 (interquartile range 56\u201374) years, 60.8% male. Main predisposing conditions were: hematologic malignancy 151 (37.7%), severe respiratory viral infection 120 (29.9%), and chronic steroid treatment 64 (16%). Overall, 105 (26.2%) patients received L-AmB and 296 (73.8%) triazoles as initial therapy. Patients on L-AmB were more likely to have therapy changed (63.8% vs 17.2%, P &amp;lt; .001) for switching to oral triazoles (48, 71.6%), while the main reason for changing triazoles was adverse events (23, 45.1%). Overall 90-day survival rates were similar between triazole (58.8%; 95% confidence interval [CI], 53.4\u201364.7) and L-AmB (53.3%, 44.6\u201363.8) groups (P = .3). IPTW-weighted Kaplan-Meier survival curves from day 7 landmark demonstrated an adjusted hazard ratio of 1.43 (95% CI, 0.87\u20132.33; P = .61).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Primary L-AmB therapy was well tolerated and associated with similar survival rates as triazoles. Further studies are needed to investigate the impact of primary L-AmB on IA patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf777","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T12:33:56Z","timestamp":1765802036000},"source":"Crossref","is-referenced-by-count":1,"title":["Primary Therapy for Invasive Aspergillosis With Triazoles or L-AmB: A Multicenter Retrospective Study"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3568-5973","authenticated-orcid":false,"given":"Matteo","family":"Rinaldi","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna , Bologna ,","place":["Italy"]},{"name":"Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2002-4339","authenticated-orcid":false,"given":"Russell Edward","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Padua , Padua ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Susini","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Nuti","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Casarini","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6738-4147","authenticated-orcid":false,"given":"Daniele","family":"Riccucci","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Grassi","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Toschi","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bartoletti","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Milan ,","place":["Italy"]},{"name":"Infectious Disease Unit, IRCCS Humanitas Research Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Bussini","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Milan ,","place":["Italy"]},{"name":"Infectious Disease Unit, IRCCS Humanitas Research Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Fiore","family":"Bavaro","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Milan ,","place":["Italy"]},{"name":"Infectious Disease Unit, IRCCS Humanitas Research Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cento","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Milan ,","place":["Italy"]},{"name":"Microbiology, IRCCS Humanitas Research Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Diella","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Milan ,","place":["Italy"]},{"name":"Infectious Disease Unit, IRCCS Humanitas Research Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5455-8964","authenticated-orcid":false,"given":"Alessandra","family":"Belati","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, IRCCS Humanitas Research Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3544-0361","authenticated-orcid":false,"given":"Alessandro","family":"De Angelis","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, IRCCS Humanitas Research Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diletta","family":"Barbanotti","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, IRCCS Humanitas Research Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pensalfine","sequence":"additional","affiliation":[{"name":"Clinic Pharmacy Unit, IRCCS Policlinico di Sant'Orsola, University of Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ambretti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna , Bologna ,","place":["Italy"]},{"name":"Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Roncarati","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna , Bologna ,","place":["Italy"]},{"name":"Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna , Bologna ,","place":["Italy"]},{"name":"Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8273-7601","authenticated-orcid":false,"given":"Maddalena","family":"Giannella","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna , Bologna ,","place":["Italy"]},{"name":"Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"2026020409010483800_ofaf777-B1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1055\/s-0040-1702210","article-title":"Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease exacerbations","volume":"41","author":"Bulpa","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"2026020409010483800_ofaf777-B2","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3390\/diagnostics12112712","article-title":"Invasive aspergillosis in the intensive care unit","volume":"12","author":"Townsend","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"2026020409010483800_ofaf777-B3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.chest.2023.09.019","article-title":"Prevalence, risk factors, clinical features, and outcome of influenza-associated pulmonary aspergillosis in critically ill patients: a systematic review and meta-analysis","volume":"165","author":"Lu","year":"2024","journal-title":"Chest"},{"key":"2026020409010483800_ofaf777-B4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/s41564-022-01172-2","article-title":"COVID-19-associated fungal infections","volume":"7","author":"Hoenigl","year":"2022","journal-title":"Nat Microbiol"},{"key":"2026020409010483800_ofaf777-B5","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1111\/j.1600-6143.2009.02910.x","article-title":"Invasive aspergillosis in solid organ transplant recipients","volume":"9","author":"Singh","year":"2009","journal-title":"Am J Transplant"},{"key":"2026020409010483800_ofaf777-B6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/jof6020091","article-title":"COVID-19 associated pulmonary aspergillosis (CAPA)\u2014from immunology to treatment","volume":"6","author":"Arastehfar","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2026020409010483800_ofaf777-B7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/mmy\/myw114","article-title":"Invasive aspergillosis in acute myeloid leukemia: are we making progress in reducing mortality?","volume":"55","author":"Dragonetti","year":"2017","journal-title":"Med Mycol"},{"key":"2026020409010483800_ofaf777-B8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026020409010483800_ofaf777-B9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2026020409010483800_ofaf777-B10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"2026020409010483800_ofaf777-B11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cmi.2024.01.015","article-title":"How do I manage refractory invasive pulmonary aspergillosis","volume":"30","author":"Vergidis","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026020409010483800_ofaf777-B12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12281-020-00379-2","article-title":"Azole-resistant Aspergillus and echinocandin-resistant Candida\u2014what are the treatment options?","volume":"14","author":"Novak","year":"2020","journal-title":"Curr Fungal Infect Rep"},{"key":"2026020409010483800_ofaf777-B13","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1056\/NEJMra2027424","article-title":"Aspergillus infections","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"2026020409010483800_ofaf777-B14","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026020409010483800_ofaf777-B15","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00134-024-07341-7","article-title":"Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM","volume":"50","author":"Bassetti","year":"2024","journal-title":"Intensive Care Med"},{"key":"2026020409010483800_ofaf777-B16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2026020409010483800_ofaf777-B17","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00134-020-06091-6","article-title":"Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion","volume":"46","author":"Verweij","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026020409010483800_ofaf777-B18","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026020409010483800_ofaf777-B19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"2026020409010483800_ofaf777-B20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"2026020409010483800_ofaf777-B21","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2026020409010483800_ofaf777-B22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026020409010483800_ofaf777-B23","first-page":"100888","article-title":"Invasive aspergillosis in adult patients in Australia and New Zealand: 2017\u20132020","volume":"40","author":"Tio","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"2026020409010483800_ofaf777-B24","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/myc.13274","article-title":"Invasive aspergillosis in critically ill patients: review of definitions and diagnostic approaches","volume":"64","author":"Jenks","year":"2021","journal-title":"Mycoses"},{"key":"2026020409010483800_ofaf777-B25","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24 Suppl 1","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2026020409010483800_ofaf777-B26","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/myc.13241","article-title":"Azole resistance in Aspergillus isolates by different types of patients and correlation with environment\u2014an Italian prospective multicentre study (ARiA study)","volume":"64","author":"Prigitano","year":"2021","journal-title":"Mycoses"},{"key":"2026020409010483800_ofaf777-B27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00134-025-07793-5","article-title":"Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units\u2014the SAFE-ICU study","volume":"51","author":"Roberts","year":"2025","journal-title":"Intensive Care Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/2\/ofaf777\/66729078\/ofaf777.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/2\/ofaf777\/66729078\/ofaf777.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T14:01:11Z","timestamp":1770213671000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf777\/8456547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf777","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,2]]},"article-number":"ofaf777"}}